Abstract
Eph-ephrin system is emerging as a new potential target in several diseases including cancer, diabetes, neurodegenerative diseases and inflammation. In the last decade, several efforts have been made to develop small molecule antagonists of Eph receptors. Both natural and synthetic compounds were discovered with (poly) phenol and steroidal derivatives on one side and the α1 agonist doxazosin, 2,5-dimethylpyrrol- 1-yl-benzoic acids and amino acid conjugates of lithocholic acid on the other. In the present paper we critically present available data for these compounds and discuss their potential usefulness as pharmacological tools or as candidates for a lead-optimization program.
Keywords: Eph, ephrin, drug discovery, small molecules, protein-protein, antagonist.
Current Drug Targets
Title:Targeting the Eph-ephrin System with Protein-Protein Interaction (PPI) Inhibitors
Volume: 16 Issue: 10
Author(s): Massimiliano Tognolini and Alessio Lodola
Affiliation:
Keywords: Eph, ephrin, drug discovery, small molecules, protein-protein, antagonist.
Abstract: Eph-ephrin system is emerging as a new potential target in several diseases including cancer, diabetes, neurodegenerative diseases and inflammation. In the last decade, several efforts have been made to develop small molecule antagonists of Eph receptors. Both natural and synthetic compounds were discovered with (poly) phenol and steroidal derivatives on one side and the α1 agonist doxazosin, 2,5-dimethylpyrrol- 1-yl-benzoic acids and amino acid conjugates of lithocholic acid on the other. In the present paper we critically present available data for these compounds and discuss their potential usefulness as pharmacological tools or as candidates for a lead-optimization program.
Export Options
About this article
Cite this article as:
Tognolini Massimiliano and Lodola Alessio, Targeting the Eph-ephrin System with Protein-Protein Interaction (PPI) Inhibitors, Current Drug Targets 2015; 16 (10) . https://dx.doi.org/10.2174/1389450116666150825144457
DOI https://dx.doi.org/10.2174/1389450116666150825144457 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeted Alpha Therapy with 213Bi
Current Radiopharmaceuticals Cannabinoid Signaling in Glial Cells in Health and Disease
Current Neuropharmacology Stem cells contributing to postnatal skeletogenesis in the mouse bone marrow
Current Stem Cell Research & Therapy Protein Pool Maintenance During Oxidative Stress
Current Pharmaceutical Design Polyisoprenylation Potentiates the Inhibition of Polyisoprenylated Methylated Protein Methyl Esterase and the Cell Degenerative Effects of Sulfonyl Fluorides
Current Cancer Drug Targets Screening Neuroprotective Agents Through 4-hydroxynonenal, Ethanol, High Glucose, Homocysteine, Okadaic Acid, Rotenone, and Oxygen-Glucose Deprivation Induced PC12 Injury Models: A Review
Current Psychopharmacology Microdosing, Imaging Biomarkers and SPECT: A Multi-Sided Tripod to Accelerate Drug Development
Current Pharmaceutical Design Integrins in Drug Targeting-RGD Templates in Toxins
Current Pharmaceutical Design Development of NGR-Based Anti-Cancer Agents for Targeted Therapeutics and Imaging
Anti-Cancer Agents in Medicinal Chemistry Bioconversion of Isoflavones into Bioactive Equol: State of the Art
Recent Patents on Food, Nutrition & Agriculture Molecular Markers of Glioblastoma and the Potential for Integration with Imaging: the Future for Assigning Prognosis and Best Treatment Strategy
Current Molecular Imaging (Discontinued) The Induction and Repair of DNA Interstrand Crosslinks and Implications in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry A Systemic Approach to Cancer Treatment: Tumor Cell Reprogramming Focused on Endocrine-Related Cancers
Current Medicinal Chemistry A Suicide Gene Therapy Combining the Improvement of Cyclophosphamide Tumor Cytotoxicity and the Development of an Anti-Tumor Immune Response
Current Gene Therapy Targeting Telomerase for Cancer Therapy
Current Cancer Therapy Reviews Chemical Composition and Biological Activities of <i>Croton delpyi, Croton decalvatus</i> and <i>Croton caudatus</i>
The Natural Products Journal Perfusion Computed Tomography and its Application in Oncologic Practice
Current Molecular Imaging (Discontinued) ENaC in the Brain - Future Perspectives and Pharmacological Implications
Current Molecular Pharmacology Increased Expression of Matrix Metalloproteinases Mediates Thromboxane A2-Induced Invasion in Lung Cancer Cells
Current Cancer Drug Targets Muscarinic Acetylcholine Receptors: New Potential Therapeutic Targets in Antinociception and in Cancer Therapy
Recent Patents on CNS Drug Discovery (Discontinued)